Phibro Animal Health Corporation (PAHC) P/E Ratio History
UndervaluedTrading at 28.5x vs 5Y avg 36.7x · 75th percentile · Below historical baseline · Data 2014–2026
Loading P/E history...
P/E Ratio Analysis
As of September 24, 2026, Phibro Animal Health Corporation (PAHC) trades at a price-to-earnings ratio of 28.5x, with a stock price of $33.93 and trailing twelve-month earnings per share of $2.43.
The current P/E is 22% below its 5-year average of 36.7x. Over the past five years, PAHC's P/E has ranged from a low of 11.6x to a high of 286.2x, placing the current valuation at the 75th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, PAHC trades at a 20% premium to its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 164.5x.
The PEG ratio of 3.82 (P/E divided by 1883% EPS growth) suggests the stock may be expensive relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, PAHC trades roughly in line with the S&P 500 median P/E of 24.8x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PAHC DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
PAHC Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
PAHC P/E vs Peers
Animal health pharmaceuticals and vaccines peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $29B | 11.7 | 0.98 | +10% | |
| $40B | 39.3 | 2.75 | +23% | |
| $18B | 37.6 | - | -40% | |
| $11B | 22.8 | - | -41% | |
| $6B | 6.0Lowest | 0.09Best | -1% | |
| $188B | 37.6 | 2.30 | -28% | |
| $53B | 49.7 | 4.16 | +23%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
PAHC Historical P/E Data (2014–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q4 | - | $31.40 | $2.44 | 12.9x | -83% |
| FY2026 Q3 | - | $55.31 | $2.33 | 23.7x | -68% |
| FY2026 Q2 | Dec 31 2025 | $37.36 | $2.25 | 16.6x | -78% |
| FY2026 Q1 | - | $40.46 | $1.66 | 24.4x | -67% |
| FY2025 Q4 | Jun 30 2025 | $25.54 | $1.18 | 21.6x | -71% |
| FY2025 Q3 | Mar 31 2025 | $21.36 | $0.78 | 27.4x | -63% |
| FY2025 Q2 | - | $21.00 | $0.48 | 43.9x | -41% |
| FY2025 Q1 | Sep 30 2024 | $22.52 | $0.43 | 52.5x | -29% |
| FY2024 Q4 | Jun 30 2024 | $16.77 | $0.06 | 286.2x | +285% |
| FY2024 Q3 | Mar 31 2024 | $12.93 | $0.32 | 40.4x | -46% |
| FY2024 Q2 | Dec 31 2023 | $11.58 | $0.36 | 32.2x | -57% |
| FY2024 Q1 | Sep 30 2023 | $12.77 | $0.51 | 25.0x | -66% |
| FY2023 Q4 | Jun 30 2023 | $13.70 | $0.81 | 16.9x | -77% |
| FY2023 Q3 | Mar 31 2023 | $15.32 | $0.71 | 21.6x | -71% |
| FY2023 Q2 | Dec 31 2022 | $13.41 | $0.90 | 14.9x | -80% |
| FY2023 Q1 | Sep 30 2022 | $13.29 | $1.15 | 11.6x | -84% |
| FY2022 Q4 | - | $19.13 | $1.21 | 15.8x | -79% |
| FY2022 Q3 | - | $19.95 | $1.45 | 13.8x | -81% |
| FY2022 Q2 | Dec 31 2021 | $20.42 | $1.31 | 15.6x | -79% |
| FY2022 Q1 | - | $21.54 | $1.20 | 17.9x | -76% |
| FY2021 Q4 | Jun 30 2021 | $28.88 | $1.34 | 21.6x | -71% |
| FY2021 Q3 | Mar 31 2021 | $24.40 | $1.06 | 23.0x | -69% |
| FY2021 Q2 | - | $19.42 | $1.09 | 17.8x | -76% |
| FY2021 Q1 | Sep 30 2020 | $17.40 | $1.06 | 16.4x | -78% |
| FY2020 Q4 | - | $26.27 | $0.82 | 32.0x | -57% |
| FY2020 Q3 | - | $24.17 | $0.90 | 26.9x | -64% |
| FY2020 Q2 | - | $24.83 | $0.94 | 26.4x | -64% |
| FY2020 Q1 | Sep 30 2019 | $21.33 | $1.01 | 21.1x | -72% |
| FY2019 Q4 | Jun 30 2019 | $31.77 | $1.35 | 23.5x | -68% |
| FY2019 Q3 | Mar 31 2019 | $33.00 | $1.68 | 19.6x | -74% |
| FY2019 Q2 | Dec 31 2018 | $32.16 | $1.80 | 17.9x | -76% |
| FY2019 Q1 | Sep 30 2018 | $42.90 | $1.61 | 26.6x | -64% |
| FY2018 Q4 | Jun 30 2018 | $46.05 | $1.60 | 28.8x | -61% |
| FY2018 Q3 | Mar 31 2018 | $39.70 | $1.43 | 27.8x | -63% |
| FY2018 Q2 | Dec 31 2017 | $33.50 | $1.53 | 21.9x | -71% |
| FY2018 Q1 | Sep 30 2017 | $37.05 | $1.70 | 21.8x | -71% |
| FY2017 Q4 | Jun 30 2017 | $37.05 | $1.62 | 22.9x | -69% |
| FY2017 Q3 | Mar 31 2017 | $28.10 | $1.62 | 17.3x | -77% |
| FY2017 Q2 | Dec 31 2016 | $29.30 | $1.49 | 19.7x | -74% |
| FY2017 Q1 | Sep 30 2016 | $27.18 | $1.90 | 14.3x | -81% |
| FY2016 Q4 | - | $18.66 | $2.06 | 9.1x | -88% |
| FY2016 Q3 | - | $27.04 | $1.81 | 14.9x | -80% |
| FY2016 Q2 | - | $30.13 | $1.77 | 17.0x | -77% |
| FY2016 Q1 | Sep 30 2015 | $31.63 | $1.38 | 22.9x | -69% |
| FY2015 Q4 | - | $38.94 | $1.39 | 28.0x | -62% |
| FY2015 Q3 | - | $35.41 | $0.79 | 44.8x | -40% |
| FY2015 Q2 | Dec 31 2014 | $31.55 | $0.58 | 54.4x | -27% |
| FY2015 Q1 | - | $22.41 | $0.30 | 74.7x | +0% |
| FY2014 Q4 | Jun 30 2014 | $21.95 | $0.01 | 2195.0x | +2852% |
Average P/E for displayed period: 74.3x
PAHC Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
12+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
PAHC — Frequently Asked Questions
Quick answers to the most common questions about buying PAHC stock.
What is PAHC's P/E ratio?
Phibro Animal Health Corporation (PAHC) trailing twelve-month P/E ratio is 28.5x, based on TTM diluted EPS of $2.43. The 5-year average P/E is 36.7x and the historical range spans 11.6x to 286.2x.
Is PAHC stock overvalued or undervalued?
PAHC trades at 28.5x P/E, below its 5-year average of 36.7x. At the 75th percentile of its historical range (11.6x–286.2x), the stock is priced at a discount to its own history.
Is PAHC stock expensive?
No, PAHC is not expensive on a historical basis. The current P/E of 28.5x is below the 5-year average of 36.7x and sits at the 75th percentile of its valuation range.
What is PAHC's historical P/E range?
Over the past 5 years, PAHC's P/E ratio has ranged from 11.6x to 286.2x, with a median of 21.6x and an average of 36.7x. The current P/E of 28.5x places the stock at the 75th percentile of this range. Full historical data spans 2014–2026.
How does PAHC's P/E compare to the S&P 500?
PAHC trades at 28.5x P/E versus the S&P 500 median of 24.8x. The 15% premium to the market typically reflects higher expected earnings growth or quality.
How does PAHC's valuation compare to Healthcare peers?
Phibro Animal Health Corporation P/E of 28.5x compares to the Healthcare sector median of 23.7x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is PAHC's PEG ratio?
PAHC PEG ratio is 3.82, based on a P/E of 28.5x and EPS growth of 1883.3%. A PEG above 2.0 indicates a premium valuation relative to earnings growth — typically considered expensive.
What is PAHC's earnings yield?
PAHC earnings yield is 3.51%, the inverse of its 28.5x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.